Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial (LATE-MT)
An Investigator Initiated and Conducted, Prospective, Multicenter, Randomized Outcome-blinded Study of Treating Mechanical Thrombectomy Exceeding 24 Hours in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion
Sponsor: Changhai Hospital
This NA trial investigates Acute Ischemic Stroke and is currently actively recruiting participants. Changhai Hospital leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)The LATE-MT trial aims to determine that compared with standard medical care without MT, performing MT in a time window that exceeds 24 hours after last seen well, is superior on the functional outcome in AIS patients due to LVO who have been carefully selected by clinical and imaging criteria. The secondary aims include comparing with standard medical care without MT, to determine whether performing MT exceeding 24 hours of last known well is safe on the risks of any ICH, sICH, and any SAE. Other secondary aims include early improvement in neurological recovery as measured by NIHSS scores at 7 days; successful recanalization rate; imaging measurements of infarct size at 24-48 hours; death or major disability (mRS 3-6); separately on death and disability (mRS 3-5); HRQoL using Euro-QoL EQ-5D questionnaire; utility-weighted modified Rankin scale scores; duration of hospitalization; residence; and hospital service costs.
The LATE-MT trial aims to determine that compared with standard medical care without MT, performing MT in a time window that exceeds 24 hours after last seen well, is superior on the functional outcome in AIS patients due to LVO who have been carefully selected by clinical and imaging criteria. The secondary aims include comparing with standard medical care without MT, to determine whether performing MT exceeding 24 hours of last known well is safe on the risks of any ICH, sICH, and any SAE. Other secondary aims include early improvement in neurological recovery as measured by NIHSS scores at 7 days; successful recanalization rate; imaging measurements of infarct size at 24-48 hours; death or major disability (mRS 3-6); separately on death and disability (mRS 3-5); HRQoL using Euro-QoL EQ-5D questionnaire; utility-weighted modified Rankin scale scores; duration of hospitalization; residence; and hospital service costs.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Recruiting NA
-
Jan 2026 — Present [monthly]
Recruiting NA
-
Apr 2025 — Mar 2026 [monthly]
Recruiting NA
Status: Unknown → Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Apr 2023 [monthly]
Not Yet Recruiting NA
-
May 2022 — Dec 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- The George Institute for Global Health, China
For direct contact, visit the study record on ClinicalTrials.gov .